Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation + Tislelizumab + Lenvatinib in Solid Tumors
NCT06032845Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, lenvatinib in solid tumor, sponsored by Fudan University. Started Sep 2023; status: recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06032845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06032845.